0.01
0.00%
Close of 27 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About LadRx
Its shares trade under the ticker LADX. It has been listed since 10 November 1986. In the fiscal year to 31 December 2018, it reported revenue of $250,000 and a net loss of $12.7m. At that date it held total assets of $22.9m and shareholders' equity of $20.4m.
CytRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. The company is headquartered in Los Angeles, California. The firm is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. The company is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. The company is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi's sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. The company is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 10 Nov 1986
- Employees
- 2
- Website
- cytrx.com ↗
Leadership
Pay as last reported
- Dr. Jennifer SimpsonIndependent Non-Executive Chairman of the Board$97,240
- Dr. Stephen SnowdyChief Executive Officer$545,000
- Mr. John CalozChief Financial Officer, Senior Vice President, Treasurer$416,000
- Mr. Joel CaldwellIndependent Director$85,120
- Mr. Cary ClaiborneIndependent Director$87,760
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- CytRx Corp focuses on aldoxorubicin for soft tissue sarcoma in Phase III trials.
- The company has multiple clinical trials including Phase IIb for small cell lung cancer.
- DK049 is in pre-clinical development using LADR technology for anti-cancer drugs.
Weaknesses
- CytRx Corp employs only 4 full-time employees in Los Angeles.
- The company has a small workforce with limited resources for development.
- Only two employees are dedicated to biopharmaceutical research and development.
Opportunities
- Phase III trials for aldoxorubicin could lead to FDA approval for soft tissue sarcoma.
- Expanding clinical trials to additional cancer types may increase market reach.
- LADR technology offers potential for new drug conjugates in anti-cancer treatments.
Threats
- Phase III trials for aldoxorubicin face potential delays in regulatory approval.
- Competition from other biopharmaceutical companies in cancer drug development.
- Clinical trial failures could halt progress in aldoxorubicin development.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.